Feb 03, 2022/IndustryNewsGlobal/ The unexpected shifts in the global markets because of the sudden outbreak of the COVID-19 virus have brought many major and minor tremors to industries of all sizes including the SGLT2 Inhibitor Market.
It was estimated prior to this unanticipated outbreak that the SGLT2 Inhibitor Market is likely to witness a Healthy CAGR during the forecast period.
SGLT2 inhibitor is a new oral medication used for treating type 2 diseases which include dapagliflozin, canagliflozin, empagliflozin, and others. It works by preventing the kidneys from reabsorbing glucose back into the blood. It blocks these proteins and helps the kidneys to lower blood glucose levels. The excess glucose in the blood is passed out by the body via urine.
The growth of the global SGLT2 Inhibitor market is primarily driven by an increasing number of people suffering from diabetes.
- Changing lifestyle, overweight and obesity are some of the leading causes of diabetes.
- Growing demand for simple and more effective methods to treat diabetic problems is likely to drive the market growth at a substantial rate during the review period.
- Growing emphasis on new drug development with the more effective result is expected to create lucrative opportunities for the players operating in the global SGLT2 inhibitor market.
Segment Analysis
Type Trends
Based on type, the market has been segmented into dapagliflozin, canagliflozin, empagliflozin and other.
- The canagliflozin segment accounted for the largest market share in 2020 due to its widespread usage and availability of very few generic brands for this drug in the market.
- The consumption of these drugs depends on their associated side effects.
Regional Trends
Geographically, the market in North America accounted for the largest market share in 2020.
- The regional market growth can be attributed to high adoption of advanced solutions in the hospitals.
- Additionally, rising incidences of diabetes is projected to fuel the product demand further.
- The market in Asia-Pacific is expected to grow at a fastest CAGR during the review period on account of increasing prevalence of various chronic diseases and rising healthcare spending.
Key Players:
Key players operating in the global SGLT2 Inhibitor market are-
- Eli Lilly and Company (The U.S),
- C.H. Boehringer Sohn AG & Ko. KG (Germany),
- Johnson & Johnson (The U.S),
- AstraZeneca plc (UK),
- The Merck Group (Germany),
- Pfizer Inc. (The U.S),
- Tecnimede Group (The U.S),
- Unichem Laboratories Ltd. (India),
- Edifício Bluepharma (Portugal).
Features of the Report
This report offers high-quality insights and is the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research’s internal database and statistical tools.
The SGLT2 Inhibitor analysis report discusses the following heads in great detail:
- Market structure: Overview, industry life cycle analysis, supply chain analysis
- COVID-19 Impact Assessment
- Market environment analysis: Growth drivers and constraints, Porter’s five forces analysis, SWOT analysis
- Market trend and forecast analysis
- Market segment trend and forecast
- Competitive landscape and dynamics: Market share, product portfolio, product launches, etc.
- Attractive market segments and associated growth opportunities
- Emerging trends
- Strategic growth opportunities for the existing and new players
- Key success factors
Know more about Stratview Research:
Stratview Research is a global market research company and is known to offer custom research reports in varied fields such as aerospace & Defense, Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas. Our team makes sure to have deep research about the topics so that the most useful insights can be delivered to the professionals.
Need a detailed report? Get in touch with us:
Stratview Research
E-mail: sales@stratviewresearch.com
Direct: +1-313-307-4176